HEALTHCARE

The 12-month interim data from the first 16 of 22 adult patients enrolled demonstrate a mean improvement in kidney function.

"Reuters" reports that a federal judge has summoned Teva CEO Kare Schultz to discuss settling all 2,600 US suits alleging that the Israeli company fueled the opioid crisis.

The company has reported that it has switched to commercial cultivation at its farm in Ashkelon, after receiving IMC-GAP approval for the facility.

According to a report by Reuters, five pharmaceuticals and distribution companies involved in the opioids affair in the US are offering drugs worth $22 billion and services worth $28 billion.

IBI Investment House pharma analyst Steven Tepper has calculated that the cost to Teva of a $15 billion opioid settlement would be dramatically less.

The company's trial of one product failed, and it downwardly revised its sales guidance.

The settlement would run over 10 years and the drugs would include Teva's Narcan for treating opioid addiction, sources told "Bloomberg."

Dr. Tamarkin founded Foamix Pharmaceuticals, which develops and commercializes pharmaceuticals in the dermatology sector.

The company says that its CSF-1 eye drops demonstrated significant improvement in near visual acuity in a Phase 2b trial.

The Israeli biopharmaceutical company's lead candidate treats NASH, a severe form of nonalcoholic fatty liver disease.

Dr. Pnina Fishman will continue as Can-Fite BioPharma's CEO.

The merged company will be listed on Nasdaq under the name 9 Meters Biopharma.

Amot will lease back the logistics center to Teva subsidiary SLE, in a deal that will help improve Teva's current cash flow.

Former Teva CEO Jeremy Levin talks to "Globes" about Israel's biotech potential, the opioid disaster and why he shuns investing in medical cannabis.

The court still has to approve the settlement with a shareholder who sought to bring a derivative action.

The fund will invest in Israeli and global pre-revenue health-tech startups, including medical devices and digital health.

The Israeli company has developed a microbiome human discovery platform that offers a glycemic control solution for people with type II diabetes.

The new funds will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies.

Based in Rehovot, the medical device company has developed a proprietary 355nm wavelength laser technology platform.

Based on technology developed by the Technion's Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

MeaTech is developing 3D stem cell printing technology for the clean meat sector.

Dr. Carlo de Notaristefani is being replaced by Eric Drapé.

The UroGen chairman is sanguine about the prospects for the Israeli drug developer's bladder and urinary tract cancer treatments.

The Israeli company's LungVision 2.0 platform has AI Tomography, fused imaging, cloud-based machine learning and multi-modality image registration.

The company's drug successfully slowed development of Lou Gehrig's disease (ALS) in the treated patients.

The move will enhance Israel's attractiveness for investment by international pharmaceutical companies.

Israeli company NextFerm has unique technology for turning natural yeasts into industrial power players.

After Ori Yehudai's about face at cannabis company Sade, Amit Sade talks about what happened, and what makes his company different.

Shady places are about as rare as parking places in Israel's cities, but municipalities are finally addressing the matter.

Microbiome pioneer Prof. Gregor Reid sees vast potential in probiotics for our helath but dismisses 90% of the products sold on the market as useless.